Homologous and heterologous boosting of the Chadox1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, controlled, phase 2 study
<p><strong>Background: </strong>Ongoing outbreaks of coronavirus disease 2019 (COVID-19) are driven by waning immunity following primary immunizations and emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that escape vaccine-induced neutralizing...
Κύριοι συγγραφείς: | Costa Clemens, SA, Milan, EP, Sprinz, E, Neto, JC, Pacciarini, F, Li, P, Chen, HL, Smolenov, I, Pollard, A, Clemens, R |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Oxford University Press
2022
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
ανά: Camilo C. Roa, κ.ά.
Έκδοση: (2024-12-01) -
Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike
ανά: Wonyeong Jung, κ.ά.
Έκδοση: (2024-01-01) -
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
ανά: Hermosilla, E, κ.ά.
Έκδοση: (2022) -
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
ανά: Eduardo Hermosilla, κ.ά.
Έκδοση: (2022-03-01) -
Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19
ανά: Dong-In Kim, κ.ά.
Έκδοση: (2022-11-01)